NDA 203441 · Takeda Pharms USA
Gattex Kit
Teduglutide · Subcutaneous · GLP-2 Analog
NovelOrphanLast checked: Nov 19, 2026Latest source record: Aug 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Dec 21, 2012
Approved uses
4
Original approval plus efficacy supplements
Registered trials
39
22 Phase 3, 1 recruiting
FAERS reports
13,437
11,269 serious, 1,153 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 5, 2025.
GATTEX ® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support . GATTEX ® is a glucagon-like peptide-2 (GLP-2) analog indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support. ( 1 )
Mechanism: Teduglutide is an analog of naturally occurring human glucagon-like peptide-2 (GLP-2), a peptide secreted by L-cells of the distal intestine. GLP-2 is known to increase intestinal and portal blood flow and inhibit gastric acid secretion. Teduglutide binds to the glucagon-like peptide-2 receptors located in intestinal subpopulations of enteroendocrine cells, subepithelial myofibroblasts and enteric neurons of the submucosal and myenteric plexus. Activation of these receptors results in the local release of multiple mediators including insulin-like growth factor (IGF)-1, nitric oxide and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 16, 2019 Supplement 13 · Efficacy · priority review OrphanLabelLetterPediatric Other
- Dec 18, 2018 Supplement 12 · Efficacy OrphanLabelLetter
- Jun 26, 2014 Supplement 2 · Efficacy OrphanReviewLabelLetter
- Dec 21, 2012 Original approval · Type 1 - New Molecular Entity NovelOrphanReviewSummary ReviewPediatric Written Request
1 products under this application
- GATTEX KIT · TEDUGLUTIDE 5MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Teduglutide" as an intervention, any sponsor and status, largest first.
- Therapeutic Approaches to Malnutrition EnteropathyPivotal-lookingCompleted
Queen Mary University of LondonAcademic, hospital or other
NCT03716115 · 125 participants · Start May 4, 2020 · Primary completion Apr 27, 2021
Drug: N-Acetyl Glucosamine (GInNAC); Teduglutide and 1 more · For: Severe Acute Malnutrition
Sites: Lusaka, Zambia; Harare, Zimbabwe · 3 sites in all
- Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's DiseasePivotal-lookingCompleted
ShireTakeda (TAK)
NCT00072839 · 100 participants · Start Nov 12, 2003 · Primary completion Jul 28, 2005
Drug: ALX-0600; placebo and 4 more · For: Crohn's Disease
Sites: Tucson, Arizona; Lakewood, Colorado; Washington D.C., District of Columbia · 26 sites in all
ShireTakeda (TAK)
NCT00820885 · 95 participants · Start Sep 6, 2006 · Primary completion Apr 23, 2007
Drug: teduglutide; teduglutide and 1 more · For: Pharmacokinetics and Safety of Elevated Doses
Sites: Tacoma, Washington
- Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00930644 · 88 participants · Start Sep 21, 2009 · Primary completion Jan 24, 2013
Drug: teduglutide · For: Short Bowel Syndrome
Sites: La Jolla, California; New York, New York; Cleveland, Ohio · 23 sites in all
- Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) SubjectsPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00798967 · 86 participants · Start Nov 25, 2008 · Primary completion Jan 25, 2011
Drug: teduglutide; placebo · For: Short Bowel Syndrome
Sites: La Jolla, California; Washington D.C., District of Columbia; Jacksonville, Florida · 35 sites in all
- Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel SyndromePivotal-lookingCompleted
ShireTakeda (TAK)
NCT00081458 · 84 participants · Start May 25, 2004 · Primary completion Jul 6, 2007
Drug: Placebo; Teduglutide 0.05 mg/kg/d and 1 more · For: Short Bowel Syndrome
Sites: Scottsdale, Arizona; Washington D.C., District of Columbia; Atlanta, Georgia · 32 sites in all
NycomedIndustry
NCT01028924 · 72 participants · Start Nov 2009 · Primary completion Feb 2010
Drug: Teduglutide · For: Healthy
Sites: Konstanz, Germany
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT04344717 · 70 participants · Start Dec 20, 2020 · Primary completion Sep 30, 2025
Drug: Apixaban single dose; Apixaban steady-state · For: Short Bowel Syndrome; Anticoagulation
Sites: Leuven, Belgium
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- weight decreased1,267
- vascular device infection1,178
- nausea1,106
- product dose omission issue1,074
- abdominal pain1,070
- diarrhoea1,061
- weight increased882
- dehydration876
- vomiting852
- death778
- abdominal distension726
- pyrexia632
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 40 |
| 2014 | 273 |
| 2015 | 510 |
| 2016 | 370 |
| 2017 | 369 |
| 2018 | 1,131 |
| 2019 | 864 |
| 2020 | 1,130 |
| 2021 | 2,005 |
| 2022 | 2,075 |
| 2023 | 1,685 |
| 2024 | 1,305 |
| 2025 | 1,113 |
| 2026 | 565 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of glucagon-like peptide 2 in patients with short bowel syndrome: a systematic review and network meta-analysis.
Sabra HK, Remeih GS, Kereet IM, et al. · J Gastrointest Surg 2024 · Systematic Review, Network Meta-Analysis
- Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis.
Bioletto F, D'Eusebio C, Merlo FD, et al. · Nutrients 2022 · Meta-Analysis, Systematic Review
- Teduglutide for the treatment of low-output enterocutaneous fistula - A pilot randomized controlled study.
Yeh DD, Vasileiou G, Abdul Jawad K, et al. · Clin Nutr ESPEN 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Glucagon-like peptide-2 mobilizes lipids from the intestine by a systemic nitric oxide-independent mechanism.
Xiao C, Stahel P, Morgantini C, et al. · Diabetes Obes Metab 2019 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.
Chiba M, Masumoto K, Kaji T, et al. · J Pediatr Gastroenterol Nutr 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- [Review of real-life teduglutide experience].
Campos Martín C, Tejera Pérez C, Virgili-Casas N, et al. · Nutr Hosp 2023 · Review, Meta-Analysis
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.